# Long-term survival following multimodal therapy for lung cancer with hepatic metastasis: a case report

## TL;DR

A lung cancer patient with liver metastases achieved long-term survival through a combination of immunotherapy, chemotherapy, and surgery.

## Contribution

This case report suggests that multimodal therapy may offer long-term survival in lung cancer with liver metastases.

## Key findings

- Combined immunotherapy and chemotherapy led to significant tumor regression in both lung and liver.
- Surgical resection and radiofrequency ablation resulted in a pathological complete response and no recurrence.
- Multimodal therapy may confer long-term survival benefits in selected patients with oligometastatic disease.

## Abstract

The liver serves as a predominant metastatic site in advanced lung cancer, with patients developing hepatic metastases demonstrating particularly dismal prognosis and a median survival of approximately 5 months. Currently, no consensus has been established regarding optimal therapeutic strategies for lung cancer with liver metastases.

A patient with advanced lung cancer and oligometastatic liver metastases achieved significant tumor regression in both pulmonary and hepatic lesions following combined immunotherapy and chemotherapy. Subsequent radiofrequency ablation was performed for the liver metastasis, while surgical resection of the primary lung lesion resulted in pathological complete response (pCR). The patient has maintained long-term survival without evidence of disease recurrence.

For patients with advanced lung cancer and oligometastatic liver metastases demonstrating favorable response to combined immunotherapy and chemotherapy, consolidative surgical resection with adjunctive liver-directed local therapy may be considered, potentially conferring long-term survival benefits.